Literature DB >> 6849607

Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy.

D J Winston, D V Dudnick, M Chapin, W G Ho, R P Gale, W J Martin.   

Abstract

From January 1977 to June 1980, coagulase-negative staphylococci caused bacteremia in 22 (17%) of 130 patients receiving immunosuppressive therapy and were the most common cause of all bacteremias. Sixteen (73%) of the 22 patients had granulocytopenia, and eight were isolated in a laminar air-flow room. A Broviac or Hickman central intravenous (IV) catheter was present in 20 (91%) of 22 patients, and soft-tissue inflammation at the catheter exit site was a significant risk factor for bacteremia. Except for debilitating fevers and local mucocutaneous infections, there were no distinguishing clinical features in patients with bacteremia. Most infections responded to cefazolin sodium or vancomycin hydrochloride therapy; catheter removal was necessary in only seven patients. These data show that coagulase-negative staphylococci can be important pathogens in patients receiving immunosuppressive therapy, even when the patients are isolated in a laminar air-flow room, if normal mucocutaneous, host-defence barriers are interrupted by IV catheter-insertion or chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849607

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  50 in total

1.  Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Authors:  D Yamamura; R Gucalp; P Carlisle; M Cimino; J Roberts; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Evaluation of MicroScan Rapid Pos Combo panels for identification of staphylococci.

Authors:  L Stoakes; B C Schieven; E Ofori; P Ewan; R Lannigan; Z Hussain
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

3.  Antibacterial activities of antineoplastic agents.

Authors:  C A Bodet; J H Jorgensen; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

4.  Bactericidal activity of oxacillin against beta-lactamase-hyperproducing Staphylococcus aureus.

Authors:  G L Woods; P Yam
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

5.  Evaluation of Staph ID 32 system and Staph-Zym system for identification of coagulase-negative staphylococci.

Authors:  J Renneberg; K Rieneck; E Gutschik
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

6.  Role of the Staphylococcus epidermidis slime layer in experimental tunnel tract infections.

Authors:  C C Patrick; M R Plaunt; S V Hetherington; S M May
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

7.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

8.  Staphylococcus simulans septicemia in a patient with chronic osteomyelitis and pyarthrosis.

Authors:  B M Males; W R Bartholomew; D Amsterdam
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

9.  Three-step empiric treatment for severely neutropenic patients with fever: ceftazidime--vancomycin--amphotericin B.

Authors:  H Koeppler; K H Pflueger; R Seitz; K Havemann
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

10.  Association of slime with pathogenicity of coagulase-negative staphylococci causing nosocomial septicemia.

Authors:  M A Ishak; D H Gröschel; G L Mandell; R P Wenzel
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.